TY - JOUR
T1 - First-line treatment of advanced ovarian cancer
T2 - Current research and perspectives
AU - Marchetti, Claudia
AU - Pisano, Carmela
AU - Facchini, Gaetano
AU - Bruni, Giovanni Salvatore
AU - Magazzino, Francesca Paola
AU - Losito, Simona
AU - Pignata, Sandro
PY - 2010/1
Y1 - 2010/1
N2 - Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival. To date, intensive surgical staging and cytoreduction, followed by primary chemotherapy with the carboplatin-paclitaxel regimen, are considered the gold standard for the management of this disease. Nevertheless, despite good initial response to systemic therapy after optimal debulking surgery, the long-term survival remains poor, with a high risk of recurrence. Furthermore, medical therapy of ovarian cancer impacts quality of life owing to the common occurrence of chemotherapy side effects, such as alopecia, neurotoxicity and fatigue. In order to improve the efficacy and reduce the toxicity of first-line chemotherapy, more than 10,000 women have been involved in worldwide randomized trials in the last 10 years. Several treatment alternatives have been investigated, such as intraperitoneal chemotherapy, alternative doublets and triplet regimens, in the effort to find an optimal first-line treatment strategy. In this review we discuss the results of these trials, the recent progresses and the most important ongoing studies, including those with emerging target and biological agents.
AB - Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival. To date, intensive surgical staging and cytoreduction, followed by primary chemotherapy with the carboplatin-paclitaxel regimen, are considered the gold standard for the management of this disease. Nevertheless, despite good initial response to systemic therapy after optimal debulking surgery, the long-term survival remains poor, with a high risk of recurrence. Furthermore, medical therapy of ovarian cancer impacts quality of life owing to the common occurrence of chemotherapy side effects, such as alopecia, neurotoxicity and fatigue. In order to improve the efficacy and reduce the toxicity of first-line chemotherapy, more than 10,000 women have been involved in worldwide randomized trials in the last 10 years. Several treatment alternatives have been investigated, such as intraperitoneal chemotherapy, alternative doublets and triplet regimens, in the effort to find an optimal first-line treatment strategy. In this review we discuss the results of these trials, the recent progresses and the most important ongoing studies, including those with emerging target and biological agents.
KW - Bevacizumab
KW - Chemotherapy
KW - Intraperitoneal
KW - Ovarian cancer
KW - Paclitaxel
KW - Pegylated liposomal doxorubicin
KW - Target therapy
UR - http://www.scopus.com/inward/record.url?scp=74749089991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74749089991&partnerID=8YFLogxK
U2 - 10.1586/ERA.09.167
DO - 10.1586/ERA.09.167
M3 - Article
C2 - 20014885
AN - SCOPUS:74749089991
VL - 10
SP - 47
EP - 60
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 1
ER -